about
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology.Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.Hepatitis C virus drug resistance-associated substitutions: State of the art summary.Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro.Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.Discovery of fluorobenzimidazole HCV NS5A inhibitors.Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.An interferon-free antiviral regimen for HCV after liver transplantation.Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.High potency improvements to weak aryl uracil HCV polymerase inhibitor leads.Development of a cell-based assay for high-throughput screening of inhibitors against HCV genotypes 1a and 1b in a single well.Exploratory study of oral combination antiviral therapy for hepatitis C.A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.
P50
Q27472610-0C87BD33-8C51-4EA7-A623-0B9EC2F1C177Q33285375-72767FE4-B141-41CB-A37A-D06298D233D9Q36158361-A08C5A80-7059-4084-BEE4-EFA9F46FDC93Q37309080-CCF98B2A-7502-42B2-922A-B9D20EE0287FQ37831450-A15F95D0-D996-4FED-BFD6-06B5AD0F5379Q38367590-E919710A-B0E7-4E1C-BBB7-51FBD7D3D498Q38376454-A67C9B16-69E4-49AD-8323-5B246CD62369Q38415846-C69475FF-043F-4A6B-9746-1DE99FBA265FQ38533619-E3C3BD25-304A-4C01-A46D-99EA0D1AF97EQ38839766-36F72CCC-37DB-4D66-9C78-1AD28706D722Q38934649-284BED29-13BD-4E67-8E52-B558EF7364BEQ39036500-145E7A77-8B1B-4FA2-A135-7428EFF91AE2Q40121401-E01B76B6-F43F-4A3F-8E59-C5C5FF8B234CQ40239703-E81D9922-9096-4554-BA8D-E28B71A1A4D7Q40242818-302FB845-A534-49AC-B79F-BE4A3E186936Q40337619-ED01D9D7-1FE7-4B92-B1F8-840EE456A6F2Q40515316-03BF7D2B-821D-4FFF-8959-54714C3A7CABQ41110328-56415CC5-7099-4F4D-867F-95B64497C328Q41145466-C5E4130A-FDC3-42ED-8F2C-1B29086812FDQ41359261-ABEEA8E9-44D7-423A-9994-6ACE8ACD06ECQ41508623-059D65A6-5EB7-4E80-93D8-C60FC2C22D50Q41633072-55F714CC-9FA6-4453-9B42-E02C55645720Q41668021-32B882EE-3B69-4BC7-8BC1-A16249F0381FQ41694415-1B6A7444-3C87-4440-8F02-111276F3B38DQ41729517-39D10665-EAF7-4AFE-AA2D-5F69F2B0F979Q41934673-33B1C47A-C78D-4099-AFF4-695EC9C0B22CQ42120771-E475825C-72DF-4A6D-B22A-4D569BEDF255Q42225540-64219105-0CE7-46D4-AAB9-A6E2AEEC68E3Q42225545-31A06912-AE40-4696-8126-CA38258CBCA3Q42243136-18D552FF-352F-41BC-ADDC-59E991B731B3Q42288984-FFFADC8F-CB9D-446F-A1EA-F760F1931E53Q42984770-5FB4F2AC-F250-42A0-94B1-F03596C2A09EQ42987725-D9E378C1-1369-48A1-ADD1-2695FE6058C9Q42989590-932DA072-B016-4CC7-A573-D39F0C089282Q43038860-D66E5D07-BE8A-4B51-AC26-8DA857001864Q45325504-AB7B59A4-BA8F-49A1-9D91-8A487420A749
P50
name
Tami Pilot-Matias
@ast
Tami Pilot-Matias
@en
Tami Pilot-Matias
@es
Tami Pilot-Matias
@nl
type
label
Tami Pilot-Matias
@ast
Tami Pilot-Matias
@en
Tami Pilot-Matias
@es
Tami Pilot-Matias
@nl
prefLabel
Tami Pilot-Matias
@ast
Tami Pilot-Matias
@en
Tami Pilot-Matias
@es
Tami Pilot-Matias
@nl